SOLICITATION NOTICE
R -- Recommendation and guidance towards drug resistance in solid tumor oncology patients
- Notice Date
- 9/7/2010
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100237-AV
- Archive Date
- 10/2/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Clinical Sciences (DCS), Medical Oncology Branch (MOB), Molecular and Experimental Therapeutics section plans to procure on a sole source basis, biophysicist services to provide recommendation and guidance towards drug resistance in solid tumor oncology patients for the NCI with Wilfred D. Stein; 10808 Clermont Ave.; Garrett Park, Maryland; 20896-0446. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.5 to use simplified procedures for commercial acquisitions. The North American Industry Classification System Code is 541990 the business size standard is $7M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance for this procurement shall be six (6) months from the date of award. The Molecular Therapeutics and Experimental Therapeutics Sections of the Medical Oncology Branch, CCR, NCI is focused on the mechanism of activity and clinical efficacy of histone deacetylase inhibitors (HDI), as well the targeting of the ABC transporter ABCG2 in drug uptake and resistance to chemotherapy. NCI researches drug interaction involving the synergy of HDIs with cytotoxic chemotherapy against solid tumors to develop strategies to overcome intrinsic resistance to therapy. Currently drug response, patient survival and drug resistance needs to be validated. The current objective is to complete comparison analysis of drug resistance and non-resistant patient samples that have been obtained from a pharmaceutical company utilizing the mathematical model (SAGE database) that discerns a growth rate constant when both tumor regression and growth are occurring. Contractor Requirements: The Contractor shall be a biophysicist with a doctorate level of training, and capable of performing the mathematical model (SAGE). The contractor shall have experience on membrane transport with expertise in pioneering work on membrane transport, including studies on the glucose transporter, Na++/K+ ATPase, and the calcium pump. Contractor Tasks: The contractor shall complete the kinetic analysis of 900 patient samples to include exponential growth equations and rate constants. Samples were previously obtained from the pharmaceutical company, Pfizer, through a technical transfer via the NIH Tech Transfer Department. The Contractor shall report findings via SAS and Excel spreadsheets and compile a final manuscript to be presented to the NCI. The proposed Contractor, Dr. Wilfred D. Stein, Emeritus Professor of Biophysics, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Israel has unique expertise on the problem of drug resistance in solid tumors. Dr. Stein has completed pioneering work on membrane transport, including studies on the glucose transporter, Na++/K+ ATPase, and the calcium pump, which are considered classics in the kinetic analysis of transporters. His assistance on these issues will be extremely beneficial to the research efforts of Medical Oncology Branch. For these reasons, no other source is known to the NCI who possess the expertise required to carry out the mission of the laboratory. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on September 17, 2010. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Ashley Virts, Contract Specialist at virtsa@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-100237-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100237-AV/listing.html)
- Record
- SN02271248-W 20100909/100908063632-451737fb12885363f31f766700a84c3b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |